150 related articles for article (PubMed ID: 37689651)
1. Neoadjuvant chemotherapy weakens the prognostic value of the pathological tumor burden score for colorectal cancer liver metastases.
Liao L; Sun H; He J; Liu Y; Pan Z; Wu X; Fan W; Peng J; Li C
BMC Surg; 2023 Sep; 23(1):271. PubMed ID: 37689651
[TBL] [Abstract][Full Text] [Related]
2. The survival benefit of neoadjuvant chemotherapy for resectable colorectal liver metastases with high tumor burden score.
Yonekawa Y; Uehara K; Mizuno T; Aiba T; Ogura A; Mukai T; Yokoyama Y; Ebata T; Kodera Y; Nagino M
Int J Clin Oncol; 2021 Jan; 26(1):126-134. PubMed ID: 33074351
[TBL] [Abstract][Full Text] [Related]
3. Parenchymal-sparing hepatectomy for colorectal liver metastases reduces postoperative morbidity while maintaining equivalent oncologic outcomes compared to non-parenchymal-sparing resection.
Andreou A; Gloor S; Inglin J; Di Pietro Martinelli C; Banz V; Lachenmayer A; Kim-Fuchs C; Candinas D; Beldi G
Surg Oncol; 2021 Sep; 38():101631. PubMed ID: 34298267
[TBL] [Abstract][Full Text] [Related]
4. Response to preoperative chemotherapy: impact of change in total burden score and mutational tumor status on prognosis of patients undergoing resection for colorectal liver metastases.
Ruzzenente A; Bagante F; Ratti F; Beal EW; Alexandrescu S; Merath K; Makris EA; Poultsides GA; Margonis GA; Weiss MJ; Popescu I; Aldrighetti L; Guglielmi A; Pawlik TM
HPB (Oxford); 2019 Sep; 21(9):1230-1239. PubMed ID: 30792047
[TBL] [Abstract][Full Text] [Related]
5. Resection of Colorectal Liver Metastasis: Prognostic Impact of Tumor Burden vs KRAS Mutational Status.
Tsilimigras DI; Hyer JM; Bagante F; Guglielmi A; Ruzzenente A; Alexandrescu S; Poultsides G; Sasaki K; Aucejo F; Pawlik TM
J Am Coll Surg; 2021 Apr; 232(4):590-598. PubMed ID: 33383214
[TBL] [Abstract][Full Text] [Related]
6. Changes in serum lactate dehydrogenase levels as markers of pathological response and prognosis in colorectal liver metastases patients receiving neoadjuvant chemotherapy followed by resection.
Chen J; Chen Q; Yao J; Jiang Y; Zhou J; Zhao H; Cai J
Ann Palliat Med; 2021 Oct; 10(10):10276-10292. PubMed ID: 34551571
[TBL] [Abstract][Full Text] [Related]
7. The Tumor Burden Score: A New "Metro-ticket" Prognostic Tool For Colorectal Liver Metastases Based on Tumor Size and Number of Tumors.
Sasaki K; Morioka D; Conci S; Margonis GA; Sawada Y; Ruzzenente A; Kumamoto T; Iacono C; Andreatos N; Guglielmi A; Endo I; Pawlik TM
Ann Surg; 2018 Jan; 267(1):132-141. PubMed ID: 27763897
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy versus upfront surgery as the initial treatment for patients with resectable, synchronous colorectal cancer liver metastases.
Lee JM; Han YD; Cho MS; Hur H; Lee KY; Kim NK; Min BS
J Surg Oncol; 2023 Sep; 128(4):549-559. PubMed ID: 37288777
[TBL] [Abstract][Full Text] [Related]
9. [Comparative study on prognosis of neoadjuvant chemotherapy followed by hepatic surgery versus upfront surgery in patients with synchronous colorectal liver metastasis].
Wang LJ; Wang HW; Jin KM; Liu W; Bao Q; Wang K; Xing BC
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):248-255. PubMed ID: 34645169
[No Abstract] [Full Text] [Related]
10. The prognostic utility of the "Tumor Burden Score" based on preoperative radiographic features of colorectal liver metastases.
Sasaki K; Margonis GA; Andreatos N; Zhang XF; Buettner S; Wang J; Deshwar A; He J; Wolfgang CL; Weiss M; Pawlik TM
J Surg Oncol; 2017 Sep; 116(4):515-523. PubMed ID: 28543544
[TBL] [Abstract][Full Text] [Related]
11. Is neoadjuvant chemotherapy appropriate for patients with resectable liver metastases from colorectal cancer?
Hirokawa F; Asakuma M; Komeda K; Shimizu T; Inoue Y; Kagota S; Tomioka A; Uchiyama K
Surg Today; 2019 Jan; 49(1):82-89. PubMed ID: 30255329
[TBL] [Abstract][Full Text] [Related]
12. Effect of tumour size ratio on liver recurrence-free survival of patients undergoing hepatic resection for colorectal liver metastases.
Zhai Y; Bai W; Zhou J; Dong Q; Zhang J
BMC Cancer; 2022 Jan; 22(1):103. PubMed ID: 35078439
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Outcomes of Perioperative Versus Neoadjuvant Chemotherapy for Resectable Colorectal Liver Metastases: An International Multicentre Propensity-Score Matched Analysis with Stratification by Contemporary Risk-Scoring.
Di Martino M; Primavesi F; Syn N; Dorcaratto D; de la Hoz Rodríguez Á; Dupré A; Piardi T; Rhaiem R; Blanco Fernández G; de Armas Conde N; Rodríguez Sanjuán JC; Fernández Santiago R; Fernández-Moreno MC; Ferret G; López Ben S; Suárez Muñoz MÁ; Perez-Alonso AJ; Koh YX; Jones R; Martín-Pérez E
Ann Surg Oncol; 2022 Oct; 29(11):6829-6842. PubMed ID: 35849284
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Evaluation of Relapse Risk (CERR) Score for Colorectal Liver Metastases: Development and Validation.
Chen Y; Chang W; Ren L; Chen J; Tang W; Liu T; Jian M; Liu Y; Wei Y; Xu J
Oncologist; 2020 Jul; 25(7):e1031-e1041. PubMed ID: 32181531
[TBL] [Abstract][Full Text] [Related]
15. Interaction of margin status and tumour burden determines survival after resection of colorectal liver metastases: A retrospective cohort study.
Mao R; Zhao JJ; Bi XY; Zhang YF; Li ZY; Zhou JG; Zhao H; Cai JQ
Int J Surg; 2018 May; 53():371-377. PubMed ID: 29229309
[TBL] [Abstract][Full Text] [Related]
16. Neo-adjuvant Chemotherapy-Induced Neutropenia Is Associated with Histological Responses and Outcomes after the Resection of Colorectal Liver Metastases.
Chen Q; Wu C; Zhao H; Wu J; Zhao J; Bi X; Li Z; Huang Z; Zhang Y; Zhou J; Cai J
J Gastrointest Surg; 2020 Mar; 24(3):659-670. PubMed ID: 30937711
[TBL] [Abstract][Full Text] [Related]
17. Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases.
Wang Y; Yuan YF; Lin HC; Li BK; Wang FH; Wang ZQ; Ding PR; Chen G; Wu XJ; Lu ZH; Pan ZZ; Wan DS; Sun P; Yan SM; Xu RH; Li YH
Chin J Cancer; 2017 Oct; 36(1):78. PubMed ID: 28969708
[TBL] [Abstract][Full Text] [Related]
18. From the completion of neoadjuvant chemotherapy to surgery for colorectal cancer liver metastasis: What is the optimal timing?
Chen Q; Mao R; Zhao J; Bi X; Li Z; Huang Z; Zhang Y; Zhou J; Zhao H; Cai J
Cancer Med; 2020 Nov; 9(21):7849-7862. PubMed ID: 32886456
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of margin status in liver resections for colorectal metastases after bevacizumab.
Sasaki K; Margonis GA; Andreatos N; Wilson A; Weiss M; Wolfgang C; Sergentanis TN; Polychronidis G; He J; Pawlik TM
Br J Surg; 2017 Jun; 104(7):926-935. PubMed ID: 28266705
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of a novel biomarker combining DNA ploidy and tumor burden score for initially resectable liver metastases from patients with colorectal cancer.
Peng J; Li W; Fan W; Zhang R; Li X; Xiao B; Dong Y; Wan D; Pan Z; Lin J; Wu X
Cancer Cell Int; 2021 Oct; 21(1):554. PubMed ID: 34688293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
